Cargando…

2389. Effect of Rezafungin on QT Interval in Healthy Subjects

BACKGROUND: Rezafungin (RZF), a novel, once-weekly echinocandin for treatment and prophylaxis of invasive fungal infections, successfully met safety and efficacy endpoints in Phase 2 and is advancing to Phase 3 studies. RZF is the first echinocandin to undergo a definitive QT evaluation. METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flanagan, Shawn, Goodman, Daniel B, Rao, Pallavi, Jandourek, Alena, O’Reilly, Terry, Sandison, Taylor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255498/ http://dx.doi.org/10.1093/ofid/ofy210.2042

Ejemplares similares

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin
por: Huguet, Jade, et al.
Publicado: (2021)

1286. Pharmacokinetics, Excretion, and Mass Balance of [(14)C]-Rezafungin Following Intravenous (IV) Administration in Healthy Adults
por: Ong, Voon, et al.
Publicado: (2020)

1174. Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations
por: Flanagan, Shawn, et al.
Publicado: (2020)

Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
por: Flanagan, Shawn, et al.
Publicado: (2023)

Metabolism, Excretion, and Mass Balance of [(14)C]-Rezafungin in Animals and Humans
por: Ong, Voon, et al.
Publicado: (2022)

A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects
por: Gu, Kenan, et al.
Publicado: (2022)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

637. Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Vazquez, Jose A, et al.
Publicado: (2020)

P28 Rezafungin efficacy and safety in immunocompromised patients: sub-analyses of the Phase 3 trial in treatment of candidaemia and invasive candidiasis
por: Sandison, Taylor, et al.
Publicado: (2023)

Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections
por: Rubino, Christopher M., et al.
Publicado: (2021)

2389. Surveillance evaluation of COVID-19 pharmacovigilance—Karakalpakstan, Uzbekistan, 2022
por: Tursinov, Yunis, et al.
Publicado: (2023)

Dabigatran Does Not Prolong the QT Interval with Supratherapeutic Exposure: a Thorough QT Study in Healthy Subjects
por: Ring, Arne, et al.
Publicado: (2013)

P27 Rezafungin treatment of candidaemia and invasive candidiasis: outcomes stratified by baseline renal function—analysis of the Phase 2 + Phase 3 trials
por: Sandison, Taylor, et al.
Publicado: (2023)

2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study
por: Thompson, George R, et al.
Publicado: (2018)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

Acute effects of coffee on QT interval in healthy subjects
por: Buscemi, Silvio, et al.
Publicado: (2011)

2389. Assessing the Time Course of Proton Pump Inhibitor Use and Clostridioides difficile Infection
por: Panagos, Katherine, et al.
Publicado: (2019)

1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Thompson, George R, et al.
Publicado: (2020)

1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus
por: Wiederhold, Nathan P., et al.
Publicado: (2019)

Issues in QT interval measurement
por: Lanjewar, Pallavi, et al.
Publicado: (2004)

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2018)

2400. Activity of a Long-Acting Echinocandin, Rezafungin, Tested Against Invasive Fungal Isolates Collected Worldwide
por: Pfaller, Michael A, et al.
Publicado: (2018)

P29 Outcomes by baseline pathogen and susceptibility in the ReSTORE Phase 3 trial of rezafungin once weekly compared with caspofungin once daily in patients with candidaemia and/or invasive candidiasis
por: Thompson, G R, et al.
Publicado: (2023)

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QT(c) interval in healthy subjects
por: Darpö, Börje, et al.
Publicado: (2013)

Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects
por: Green, Justin A, et al.
Publicado: (2014)

Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects
por: Täubel, Jörg, et al.
Publicado: (2016)

2115. Activity of a Long-Acting Echinocandin Rezafungin and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018
por: Pfaller, Michael A, et al.
Publicado: (2019)

Correlation between QT interval and serum level of calcium
por: Factore, LAP, et al.
Publicado: (1997)

Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy
por: Miesel, Lynn, et al.
Publicado: (2019)

P22 Patient-level meta-analysis of efficacy and safety from STRIVE and ReSTORE: randomized, double-blinded, multicentre Phase 2 and Phase 3 trials of rezafungin in the treatment of candidaemia and/or invasive candidiasis
por: Soriano, A, et al.
Publicado: (2023)

Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects
por: Hong, Taegon, et al.
Publicado: (2015)

Model‐Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion
por: Cirincione, Brenda, et al.
Publicado: (2017)

1731. Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021
por: Carvalhaes, Cecilia G, et al.
Publicado: (2022)

The Measurement of the QT Interval
por: Postema, Pieter G, et al.
Publicado: (2014)

The QT Interval in Research
por: Somberg, John
Publicado: (2021)

Abemaciclib does not increase the corrected QT interval in healthy participants
por: Chappell, Jill C., et al.
Publicado: (2023)

Effect of QT interval-prolonging drugs taken in pregnancy on the neonatal QT interval
por: Michel, Holger, et al.
Publicado: (2023)

Title: Risk factors of prolonged corrected QT interval among patients with mental disorders
por: Smaoui, N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5kls2470etaigrjml6ltpfv34e